GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (NAS:HBIO) » Definitions » Cyclically Adjusted Revenue per Share

Harvard Bioscience (Harvard Bioscience) Cyclically Adjusted Revenue per Share : $3.47 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Harvard Bioscience Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Harvard Bioscience's adjusted revenue per share for the three months ended in Dec. 2023 was $0.660. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.47 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Harvard Bioscience's average Cyclically Adjusted Revenue Growth Rate was -1.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -0.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Harvard Bioscience was 8.10% per year. The lowest was -0.20% per year. And the median was 1.30% per year.

As of today (2024-04-28), Harvard Bioscience's current stock price is $3.62. Harvard Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $3.47. Harvard Bioscience's Cyclically Adjusted PS Ratio of today is 1.04.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Harvard Bioscience was 2.42. The lowest was 0.42. And the median was 1.17.


Harvard Bioscience Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Harvard Bioscience's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Cyclically Adjusted Revenue per Share Chart

Harvard Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.54 3.41 3.50 3.52 3.47

Harvard Bioscience Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.52 3.55 3.54 3.53 3.47

Competitive Comparison of Harvard Bioscience's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's Cyclically Adjusted PS Ratio falls into.



Harvard Bioscience Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Harvard Bioscience's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.66/129.4194*129.4194
=0.660

Current CPI (Dec. 2023) = 129.4194.

Harvard Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.786 99.695 1.020
201406 0.818 100.560 1.053
201409 0.762 100.428 0.982
201412 0.902 99.070 1.178
201503 0.783 99.621 1.017
201506 0.822 100.684 1.057
201509 0.758 100.392 0.977
201512 0.836 99.792 1.084
201603 0.793 100.470 1.021
201606 0.766 101.688 0.975
201609 0.728 101.861 0.925
201612 0.768 101.863 0.976
201703 0.523 102.862 0.658
201706 0.546 103.349 0.684
201709 0.537 104.136 0.667
201712 0.620 104.011 0.771
201803 0.755 105.290 0.928
201806 0.874 106.317 1.064
201809 0.775 106.507 0.942
201812 0.908 105.998 1.109
201903 0.749 107.251 0.904
201906 0.784 108.070 0.939
201909 0.721 108.329 0.861
201912 0.816 108.420 0.974
202003 0.620 108.902 0.737
202006 0.606 108.767 0.721
202009 0.618 109.815 0.728
202012 0.796 109.897 0.937
202103 0.678 111.754 0.785
202106 0.727 114.631 0.821
202109 0.728 115.734 0.814
202112 0.811 117.630 0.892
202203 0.698 121.301 0.745
202206 0.686 125.017 0.710
202209 0.647 125.227 0.669
202212 0.683 125.222 0.706
202303 0.701 127.348 0.712
202306 0.679 128.729 0.683
202309 0.594 129.860 0.592
202312 0.660 129.419 0.660

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Harvard Bioscience  (NAS:HBIO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Harvard Bioscience's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.62/3.47
=1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Harvard Bioscience was 2.42. The lowest was 0.42. And the median was 1.17.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Harvard Bioscience Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Bioscience (Harvard Bioscience) Business Description

Traded in Other Exchanges
Address
84 October Hill Road, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Executives
James W Green director, officer: Chief Executive Officer 12525 CHADRON AVENUE, HAWTHORNE CA 90250
Alan I Edrick director 20200 SUNBURST STREET, CHATSWORTH CA 91311
Jennifer Cote officer: Interim CFO C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Bertrand Loy director C/O ENTEGRIS, INC., 129 CONCORD RD, BILLERICA MA 01821
Thomas W Loewald director 81 WYMAN STREET, WALTHAM MA 02451
John F Kennedy director C/O NET PERCEPTIONS INC, 7700 FRANCE AVE. SOUTH, EDINA MN 55435
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Susan M. Steele director C/O HILL INTERNATIONAL, INC., 2005 MARKET ST., 17TH FLOOR, PHILADELPHIA PA 19103
Kenneth Fletcher Olson officer: Chief Operating Officer C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Michael A. Rossi officer: Chief Financial Officer C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Yash Singh officer: Executive Vice President C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Jeffrey Duchemin officer: Chief Executive Officer 14 EASTLAND TERRACE, HAVERHILL MA 01830
Kamalam Unninayar officer: Chief Financial Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
George Uveges director C/O MFIC CORPORATION, 30 OSSIPEE ROAD, NEWTON MA 02464